The clinical management of bipolar disorder complexity using a stratified model

Bipolar Disorders

Volumn 14, Issue SUPPL.2, 2012, Pages 66-89

  Malhi, Gin S ^a,b   Bargh, Danielle M ^a,b   Cashman, Emma ^a,b   Frye, Mark A ^c   Gitlin, Michael ^d  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute treatment; Bipolar disorder; Evidence based review; Guidelines; Maintenance treatment; Treatment

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; BENZODIAZEPINE; CARBAMAZEPINE; LAMOTRIGINE; LEVOTHYROXINE; LITHIUM; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

AGE DISTRIBUTION; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BIOLOGICAL RHYTHM; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR II DISORDER; BIPOLAR MANIA; CLINICAL ASSESSMENT; CLINICAL FEATURE; COGNITIVE THERAPY; COMORBIDITY; CYCLOTHYMIA; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; ENERGY; EVIDENCE BASED MEDICINE; HUMAN; HYPOMANIA; IMPULSIVENESS; IRRITABILITY; MAINTENANCE THERAPY; MEDLINE; MONOTHERAPY; MOOD CHANGE; MOOD DISORDER; NONBIOLOGICAL MODEL; ONSET AGE; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; PSYCHOEDUCATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAPID CYCLING BIPOLAR DISORDER; REVIEW; SUBSTANCE ABUSE; SUICIDAL BEHAVIOR; SYSTEMATIC REVIEW; TREATMENT CONTRAINDICATION; TREATMENT DURATION;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; BIPOLAR DISORDER; FEMALE; HUMANS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; MODELS, THEORETICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 84859880563     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2012.00993.x     Document Type: Review

References (261)

1. Lee S, Tsang A, Kessler RC et al. Rapid-cycling bipolar disorder: cross-national community study. Br J Psychiatry 2010; 196: 217-225.
2. Duffy A, Alda M, Hajek T, Sherry SB, Grof P. Early stages in the development of bipolar disorder. J Affect Disord 2010; 121: 127-135.
3. Hirschfeld RMA, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: How far have we really come? Results of the National Depressive and Manic-Depressive Association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry 2003; 64: 161-174.
4. Goldberg JF, Ernst CL. Features associated with the delayed initiation of mood stabilizers at illness onset in bipolar disorder. J Clin Psychiatry 2002; 63: 985-991.
5. National Health and Medical Research Council. A guide to the development, implementation and evaluation of clinical practice guidelines. Canberra: Commonwealth of Australia, 1998.
6. Malhi GS, Adams D, Cahill CM, Dodd S, Berk M. The management of individuals with bipolar disorder. Drugs 2009; 69: 2063-2101.
7. Malhi GS, Adams D, Berk M. The pharmacological treatment of bipolar disorder in primary care. Med J Aust 2010; 193 (Suppl. 4): 24-30.
8. Merikangas KR, Jin R, He JP et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Archiv Gen Psychiatry 2011; 68: 241-251.
9. Boylan KR, Bieling PJ, Marriott M, Begin H, Young LT, MacQueen GM. Impact of comorbid anxiety disorders on outcome in a cohort of patients with bipolar disorder. J Clin Psychiatry 2004; 65: 1106-1113.
10. Weiss R, Ostacher M, Otto M et al. Does recovery from substance use disorder matter in patients with bipolar disorder? J Clin Psychiatry 2005; 66: 730-735.
11. Simon NM, Otto MW, Wisniewski SR et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2004; 161: 2222-2229.
12. Malhi GS, Adams D, Lampe L et al. Clinical practice recommendations for bipolar disorder. Acta Psychiatrica Scandinavica, Supplementum 2009; 119 (Suppl. 439): 27-46.
13. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association, 2005.
14. Merikangas KR, Akiskal HS, Angst J et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007; 64: 543-552.
15. Judd LL, Akiskal HS, Schettler PJ et al. Psychosocial disability in the course of bipolar I and II disorders. Arch Gen Psychiatry 2005; 62: 1322-1330.
16. Judd LL, Akiskal HS, Schettler PJ et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003; 60: 261-269.
17. Bora E, Yucel M, Pantelis C, Berk M. Meta-analytic review of neurocognition in bipolar II disorder. Acta Psychiatr Scand 2011; 123: 165-174.
18. Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: Re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord 2003; 73: 123-131.
19. Swartz HA, Thase ME. Pharmacotherapy for the treatment of acute bipolar II depression: current evidence. J Clin Psychiatry 2011; 72: 356-366.
20. Bond DJ, Noronha MM, Kauer-Sant'Anna M, Lam RW, Yatham LN. Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. J Clin Psychiatry 2008; 69: 1589-1601.
21. Regeer EJ, Krabbendam L, de Graaf R, ten Have M, Nolen WA, van Os J. A prospective study of the transition rates of subthreshold (hypo)mania and depression in the general population. Psychol Med 2006; 36: 619-627.
22. Joyce PR, Luty SE, McKenzie JM et al. Bipolar II disorder: personality and outcome in two clinical samples. Aust N Z J Psychiatry 2004; 38: 433-438.
23. Alloy LB, Urošević S, Abramson LY et al. Progression along the bipolar spectrum: A longitudinal study of predictors of conversion from bipolar spectrum conditions to bipolar I and II disorders. J Abnorm Psychol 2012; 121: 16-27.
24. Zimmermann P, Bruckl T, Nocon A et al. Heterogeneity of DSM-IV major depressive disorder as a consequence of subthreshold bipolarity. Arch Gen Psychiatry 2009; 66: 1341-1352.
25. Suppes T, Marangell LB, Bernstein IH et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. J Affect Disord 2008; 111: 334-343.
26. Wang PW, Nowakowska C, Chandler RA et al. Divalproex extended-release in acute bipolar II depression. J Affect Disord 2010; 124: 170-173.
27. Winsberg ME, DeGolia SG, Strong CM, Ketter TA. Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. J Affect Disord 2001; 67: 207-212.
28. Calabrese JR, Huffman RF, White RL et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord 2008; 10: 323-333.
29. Amsterdam JD, Wang C-H, Shwarz M, Shults J. Venlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: a randomized, parallel group, open-label trial. J Affect Disord 2009; 112: 219-230.
30. Amsterdam JD, Shults J. Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode. J Clin Psychopharmacol 2010; 30: 306-311.
31. Sharma V, Khan M, Corpse C. Role of lamotrigine in the management of treatment-resistant bipolar II depression: a chart review. J Affect Disord 2008; 111: 100-105.
32. Chang JS, Moon E, Cha B, Ha K. Adjunctive lamotrigine therapy for patients with bipolar II depression partially responsive to mood stabilizers. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1322-1326.
33. Calabrese JR, Suppes T, Bowden CL et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000; 61: 841-850.
34. Amsterdam JD, Schults J. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study. Am J Psychiatry 2010; 167: 792-800.
35. Dunner DL, Stallone F, Fieve RR. Lithium carbonate and affective disorders. V: A double-blind study of prophylaxis of depression in bipolar illness. Arch Gen Psychiatry 1976; 33: 117-120.
36. Kane JM, Quitkin FM, Rifkin A, Ramos-Lorenzi JR, Nayak DD, Howard A. Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. Arch Gen Psychiatry 1982; 39: 1065-1069.
37. Fieve RR, Kumbaraci T, Dunner DL. Lithium prophylaxis of depression in bipolar I, bipolar II, and unipolar patients. Am J Psychiatry 1976; 133: 925-929.
38. Tondo L, Baldessarini RJ, Floris G. Long-term clinical effectiveness of lithium maintenance treatment in types I and II bipolar disorders. Br J Psychiatry 2001; 178 (Suppl. 41): 184-190.
39. Geddes JR, Goodwin GM, Rendell J et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010; 375: 385-395.
40. Kleindienst N, Greil W. Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study. Neuropsychobiology 2000; 42 (Suppl. 1): 2-10.
41. Colom F, Vieta E, Sanchez-Moreno J et al. Psychoeducation for bipolar II disorder: an exploratory, 5-year outcome subanalysis. J Affect Disord 2009; 112: 30-35.
42. Miklowitz DJ, Otto MW, Frank E et al. Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry 2007; 64: 419-426.
43. Swartz HA, Frank E, Frankel DR, Novick D, Houck P. Psychotherapy as monotherapy for the treatment of bipolar II depression: a proof of concept study. Bipolar Disord 2009; 11: 89-94.
44. Akiskal HS, Bourgeois ML, Angst J, Post R, Moller H, Hirschfeld R. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J Affect Disord 2000; 59 (Suppl. 1): 5-30.
45. Malhi GS, Chengappa KNR, Gershon S, Goldberg JF. Hypomania: Hype or mania? Bipolar Disord 2010; 12: 758-763.
46. Angst J, Gamma A, Bowden CL et al. Diagnostic criteria for bipolarity based on an international sample of 5, 635 patients with DSM-IV major depressive episodes. Eur Arch Psychiatry Clin Neurosci 2012; 262: 3-11.
47. Angst J, Azorin JM, Bowden CL, Perugi G, Vieta E, Gamma A, Young AH. Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode: The BRIDGE Study. Arch Gen Psychiatry 2011; 68: 791-798.
48. Benazzi F. Frequency of bipolar spectrum in 111 private practice depression outpatients. Eur Arch Psychiatry Clin Neurosci 2003; 253: 203-208.
49. Judd LL, Akiskal HS, Schetteler PJ et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59: 530-537.
50. Marangell LB, Dennehy EB, Miyahara S et al. The functional impact of subsyndromal depressive symptoms in bipolar disorder: data from STEP-BD. J Affect Disord 2009; 114: 58-67.
51. MacQueen GM, Marriott M, Begin H, Robb J, Joffe RT, Young LT. Subsyndromal symptoms assessed in longitudinal, prospective follow-up of a cohort of patients with bipolar disorder. Bipolar Disord 2003; 5: 349-355.
52. Goldberg JF, Perlis RH, Bowden CL et al. Manic symptoms during depressive episodes in 1, 380 patients with bipolar disorder: Findings from the STEP-BD. Am J Psychiatry 2009; 166: 173-181.
53. Bernhard B, Born C, Seemüeller F, Grunze H. Levetiracetam add-on treatment for bipolar patients suffering from subsyndromal symptoms: preliminary data of an open 6-months longitudinal study. Bipolar Disord 2006; 8 (Suppl. 1): 30.
54. Deckersbach T, Nierenberg AA, Kessler R et al. RESEARCH: Cognitive rehabilitation for bipolar disorder: An open trial for employed patients with residual depressive symptoms. CNS Neurosci Ther 2010; 16: 298-307.
55. Deckersbach T, Hölzel BK, Eisner LR et al. Mindfulness-based cognitive therapy for nonremitted patients with bipolar disorder. CNS Neurosci Ther 2012; 18: 133-141.
56. Dodd S, Kulkarni J, Berk L et al. A prospective study of the impact of subthreshold mixed states on the 24-month clinical outcomes of bipolar I disorder or schizoaffective disorder. J Affect Disord 2010; 124: 22-28.
57. Henry C, M'Bailara K, Desage A, Gard S, Misdrahi D, Vieta E. Towards a reconceptualization of mixed states, based on an emotional-reactivity dimensional model. J Affect Disord 2007; 101: 35-41.
58. Tohen M, Zarate CA Jr, Hennen J et al. The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry 2003; 160: 2099-2107.
59. Khalsa HMK, Salvatore P, Hennen J, Baethge C, Tohen M, Baldessarini RJ. Suicidal events and accidents in 216 first-episode bipolar I disorder patients: predictive factors. J Affect Disord 2008; 106: 179-184.
60. Minnai GP, Tondo L, Salis P et al. Secular trends in first hospitalizations for major mood disorders with comorbid substance use. Int J Neuropsychopharmacol 2006; 9: 319-326.
61. Perugi G, Akiskal HS, Micheli C, Toni C, Madaro D. Clinical characterization of depressive mixed state in bipolar-I patients: Pisa-San Diego collaboration. J Affect Disord 2001; 67: 105-114.
62. Azorin J-M, Aubrun E, Bertsch J, Reed C, Gerard S, Lukasiewicz M. Mixed states vs. pure mania in the French sample of the EMBLEM study: results at baseline and 24months-European mania in bipolar longitudinal evaluation of medication. BMC Psychiatry 2009; 9: 33.
63. Valtonen HM, Suominen K, Haukka J et al. Differences in incidence of suicide attempts during phases of bipolar I and II disorders. Bipolar Disord 2008; 10: 588-596.
64. Tohen M, Sutton VK, Calabrese JR, Sachs GS, Bowden CL. Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar 1 disorder. J Affect Disord 2009; 116: 43-50.
65. Houston JP, Tohen M, Degenhardt EK, Jamal HH, Liu LLL, Ketter TA. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study. J Clin Psychiatry 2011; 72: 1157.
66. Khazaal Y, Tapparel S, Chatton A, Rothen S, Preisig M, Zullino D. Quetiapine dosage in bipolar disorder episodes and mixed states. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 727-730.
67. Vieta E, Ramey T, Keller D, English PA, Loebel AD, Miceli J. Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study. J Psychopharmacol 2010; 24: 547-558.
68. Keck PE Jr, Versiani M, Potkin S et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003; 160: 741-748.
69. Potkin SG, Keck PE Jr, Segal S, Ice K, English P. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol 2005; 25: 301-310.
70. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord 2009; 11: 673-686.
71. Suppes T, Eudicone J, McQuade R, Pikalov A III, Carlson B. Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. J Affect Disord 2008; 107: 145-154.
72. Bowden CL, Swann AC, Calabrese JR et al. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry 2006; 67: 1501-1510.
73. McIntyre RS, Yoon J. Efficacy of antimanic treatments in mixed states. Bipolar Disord 2012; 14 (Suppl. 2): 22-36.
74. Kessing LV, Hellmund G, Geddes JR, Goodwin GM, Andersen PK. Valproate v. lithium in the treatment of bipolar disorder in clinical practice: Observational nationwide register-based cohort study. Br J Psychiatry 2011; 199: 57-63.
75. Schneck CD. Treatment of rapid-cycling bipolar disorder. J Clin Psychiatry 2006; 67 (Suppl. 11): 22-27.
76. Tyrer P. Primary article for discussion Why borderline personality disorder is neither borderline nor a personality disorder. Personal Mental Health 2009; 3: 86-95.
77. Nilsson AKK, Jorgensen CR, Straarup KN, Licht RW. Severity of affective temperament and maladaptive self-schemas differentiate borderline patients, bipolar patients, and controls. Compr Psychiatry 2010; 51: 486-491.
78. Kupka RW, Luckenbaugh DA, Post RM, Leverich GS, Nolen WA. Rapid and non-rapid cycling bipolar disorder: a meta-analysis of clinical studies. J Clin Psychiatry 2003; 64: 1483-1494.
79. Coryell W, Solomon D, Turvey C et al. The long-term course of rapid-cycling bipolar disorder. Arch Gen Psychiatry 2003; 60: 914-920.
80. Schneck CD, Miklowitz DJ, Miyahara S et al. The prospective course of rapid-cycling bipolar disorder: findings from the STEP-BD. Am J Psychiatry 2008; 165: 370-377.
81. Garcia-Amador M, Colom F, Valenti M, Horga G, Vieta E. Suicide risk in rapid cycling bipolar patients. J Affect Disord 2009; 117: 74-78.
82. Perlis RH, Ostacher MJ, Miklowitz DJ et al. Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD study. J Clin Psychiatry 2010; 71: 296-303.
83. Nierenberg AA, Akiskal HS, Angst J et al. Bipolar disorder with frequent mood episodes in the national comorbidity survey replication (NCS-R). Mol Psychiatry 2010; 15: 1075-1087.
84. Muzina DJ. Pharmacologic treatment of rapid cycling and mixed states in bipolar disorder: an argument for the use of lithium. Bipolar Disord 2009; 11 (Suppl. 2): 84-91.
85. Suppes T, Hirschfeld RM, Vieta E, Raines S, Paulsson B. Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies. World J Biol Psychiatry 2008; 9: 198-211.
86. Sanger TM, Tohen M, Vieta E et al. Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling. J Affect Disord 2003; 73: 155-161.
87. Calabrese JR, Shelton MD, Rapport DJ et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005; 162: 2152-2161.
88. Kemp DE, Gao K, Ganocy SJ et al. A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and co-occurring substance abuse or dependence. J Clin Psychiatry 2009; 70: 113-121.
89. Calabrese JR, Markovitz PJ, Kimmel SE, Wagner SC. Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. J Clin Psychopharmacol 1992; 12: 53-56.
90. Denicoff KD, Smith-Jackson EE, Disney ER, Ali S, Leverich GS, Post RM. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58: 470-478.
91. Bauer MS, Whybrow PC. Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Arch Gen Psychiatry 1990; 47: 435-440.
92. Kyaga S, Lichtenstein P, Boman M, Hultman C, Langstrom N, Landen M. Creativity and mental disorder: family study of 300 000 people with severe mental disorder. Br J Psychiatry 2011; 199: 373-379.
93. Jamison KR. Great wits and madness: more near allied? Br J Psychiatry 2011; 199: 351-352.
94. Zimmerman M, Ruggero CJ, Chelminski I, Young D. Psychiatric diagnoses in patients previously overdiagnosed with bipolar disorder. J Clin Psychiatry 2010; 71: 26-31.
95. Ruggero CJ, Zimmerman M, Chelminski I, Young D. Borderline personality disorder and the misdiagnosis of bipolar disorder. J Psychiatr Res 2010; 44: 405-408.
96. Galione J, Zimmerman M. A comparison of depressed patients with and without borderline personality disorder: implications for interpreting studies of the validity of the bipolar spectrum. J Personal Disord 2010; 24: 763-772.
97. Soler J, Pascual JC, Tiana T et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behav Res Ther 2009; 47: 353-358.
98. Pasieczny N, Connor J. The effectiveness of dialectical behaviour therapy in routine public mental health settings: an Australian controlled trial. Behav Res Ther 2011; 49: 4-10.
99. Kleindienst N, Limberger MF, Schmahl C, Steil R, Ebner-Priemer UW, Bohus M. Do improvements after inpatient dialectial behavioral therapy persist in the long term? A naturalistic follow-up in patients with borderline personality disorder. J Nerv Ment Dis 2008; 196: 847-851.
100. Bateman A. Fonagy P. 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. Am J Psychiatry 2008; 165: 631-638.
101. Bateman A, Fonagy P. Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Am J Psychiatry 2009; 166: 1355-1364.
102. Doering S, Hoerz S, Rentrop M et al. Transference-focused psychotherapy v. treatment by community psychotherapists for borderline personality disorder: randomised controlled trial. Br J Psychiatry 2010; 196: 389-395.
103. Clarkin JF, Levy KN, Lenzenweger MF, Kernberg OF. Evaluating three treatments for borderline personality disorder: A multiwave study. Am J Psychiatry 2007; 164: 922-928.
104. Farrell JM, Shaw IA, Webber MA. A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: A randomized controlled trial. J Behav Ther Exp Psychiatry 2009; 40: 317-328.
105. Fornaro M, Perugi G, Gabrielli F et al. Lifetime co-morbidity with different subtypes of eating disorders in 148 females with bipolar disorders. J Affect Disord 2010; 121: 147-151.
106. McElroy SL, Frye MA, Hellemann G et al. Prevalence and correlates of eating disorders in 875 patients with bipolar disorder. J Affect Disord 2011; 128: 191-198.
107. Altindag A, Yanik M, Nebioglu M. Comorbid personality disorders in subjects with bipolar I disorder. Int J Psychiatry Clin Prac 2006; 10: 33-37.
108. Brieger P, Ehrt U, Marneros A. Frequency of comorbid personality disorders in bipolar and unipolar affective disorders. Compr Psychiatry 2003; 44: 28-34.
109. Tamam L, Ozpoyraz N, Karatas G. Personality disorder comorbidity among patients with bipolar I disorder in remission. Acta Neuropsychiatrica 2004; 16: 175-180.
110. Beyer J, Kuchibhatla M, Gersing K, Krishnan KRR. Medical comorbidity in a bipolar outpatient clinical population. Neuropsychopharmacol 2005; 30: 401-404.
111. Carney CP, Jones LE. Medical comorbidity in women and men with bipolar disorders: a population-based controlled study. Psychosom Med 2006; 68: 684-691.
112. Tohen M, Calabrese J, Vieta E et al. Effect of comorbid anxiety on treatment response in bipolar depression. J Affect Disord 2007; 104: 137-146.
113. Gaudiano BA, Miller IW. Anxiety disorder comobidity in bipolar I disorder: relationship to depression severity and treatment outcome. Depress Anxiety 2005; 21: 71-77.
114. Azorin J-M, Kaladjian A, Adida M et al. Psychopathological correlates of lifetime anxiety comorbidity in bipolar I patients: findings from a French national cohort. Psychopathology 2009; 42: 380-386.
115. Goldstein BI, Levitt AJ. The specific burden of comorbid anxiety disorders and of substance use disorders in bipolar I disorder. Bipolar Disord 2008; 10: 67-78.
116. Rakofsky JJ, Dunlop BW. Treating nonspecific anxiety and anxiety disorders in patients with bipolar disorder: a review. J Clin Psychiatry 2011; 72: 81-90.
117. Perlis RH, Ostacher MJ, Miklowitz DJ et al. Benzodiazepine use and risk of recurrence in bipolar disorder: a STEP-BD report. J Clin Psychiatry 2010; 71: 194-200.
118. Gao K, Muzina D, Gajwani P, Calabrese JR. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry 2006; 67: 1327-1340.
119. Merikangas KR, Herrell R, Swendsen J, Rossler W, Ajdacic-Gross V, Angst J. Specificity of bipolar spectrum conditions in the comorbidity of mood and substance use disorders: results from the Zurich cohort study. Arch Gen Psychiatry 2008; 65: 47-52.
120. Leverich GS, Altshuler LL, Frye MA et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006; 163: 232-239.
121. Post RM, Altshuler LL, Leverich GS et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry 2006; 189: 124-131.
122. Freeman MP, Freeman SA, McElroy SL. The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology, and treatment issues. J Affect Disord 2002; 68: 1-23.
123. Provencher MD, Hawke LD, Thienot E. Psychotherapies for comorbid anxiety in bipolar spectrum disorders. J Affect Disord 2011; 133: 371-380.
124. Maina G, Albert U, Rosso G, Bogetto F. Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity: a randomized, single-blind, pilot study. J Clin Psychiatry 2008; 69: 609-616.
125. Sheehan DV, McElroy SL, Harnett-Sheehan K et al. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. J Affect Disord 2009; 115: 376-385.
126. Ghaemi SN, Gilmer WS, Goldberg JF et al. Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. J Clin Psychiatry 2007; 68: 1840-1844.
127. Davis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord 2005; 85: 259-266.
128. Vieta E, Martinez-Aran A, Nieto E et al. Adjunctive gabapentin treatment of bipolar disorder. Eur Psychiatry 2000; 15: 433-437.
129. Yatham LN, Fallu A, Binder CE. A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder. Acta Psychiatri Scandinav Supplementum 2007; 116 (Suppl. 434): 50-56.
130. Lydiard RB, Culpepper L, Schiöler H, Gustafsson U, Paulsson B. Quetiapine monotherapy as treatment for anxiety symptoms in patients with bipolar depression: a pooled analysis of results from 2 double-blind, randomized, placebo-controlled studies. Prim Care Companion J Clin Psychiatry 2009; 11: 215-225.
131. Ostacher MJ, Perlis RH, Nierenberg AA et al. Impact of substance use disorders on recovery from episodes of depression in bipolar disorder patients: prospective data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2010; 167: 289-297.
132. Gao K, Kemp DE, Conroy C, Ganocy SJ, Findling RL, Calabrese JR. Comorbid anxiety and substance use disorders associated with a lower use of mood stabilisers in patients with rapid cycling bipolar disorder: a descriptive analysis of the cross-sectional data of 566 patients. Int J Clin Pract 2010; 64: 336-344.
133. Sajatovic M, Ignacio RV, West JA et al. Predictors of nonadherence among individuals with bipolar disorder receiving treatment in a community mental health clinic. Compr Psychiatry 2009; 50: 100-107.
134. Strakowski SM, DelBello MP, Fleck DE, Arndt S. The impact of substance abuse on the course of bipolar disorder. Biol Psychiatry 2000; 48: 477-485.
135. Mazza M, Mandelli L, Di Nicola M et al. Clinical features, response to treatment and functional outcome of bipolar disorder patients with and without co-occurring substance use disorder: 1-year follow-up. J Affect Disord 2009; 115: 27-35.
136. Elizabeth Sublette M, Carballo JJ, Moreno C et al. Substance use disorders and suicide attempts in bipolar subtypes. J Psychiatr Res 2009; 43: 230-238.
137. Dalton EJ, Cate-Carter TD, Mundo E, Parikh SV, Kennedy JL. Suicide risk in bipolar patients: the role of co-morbid substance use disorders. Bipolar Disord 2003; 5: 58-61.
138. Levy B, Monzani BA, Stephansky MR, Weiss RD. Neurocognitive impairment in patients with co-occurring bipolar disorder and alcohol dependence upon discharge from inpatient care. Psychiatry Res 2008; 161: 28-35.
139. Azorin J-M, Bowden CL, Garay RP, Perugi G, Vieta E, Young AH. Possible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholism. Neuropsychiatr Dis Treat 2010; 6: 37-46.
140. Lagerberg TV, Larsson S, Sundet K et al. Treatment delay and excessive substance use in bipolar disorder. J Nerv Ment Dis 2010; 198: 628-633.
141. Salloum I, Douaihy A, Williams L. Diagnostic and treatment considerations: bipolar patients with comorbid substance use disorders. Psychiatr Ann 2008; 38: 716-723.
142. Kosten TR, Kosten TA. New medication strategies for comorbid substance use and bipolar affective disorders. Biol Psychiatry 2004; 56: 771-777.
143. Brady KT, Sonne SC, Anton R, Ballenger JC. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J Clin Psychiatry 1995; 56: 118-121.
144. Salloum IM, Cornelius JR, Daley DC, Kirisci L. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry 2005; 62: 37-45.
145. Myrick H, Henderson S, Brady KT, Malcom R, Measom M. Divalproex loading in the treatment of cocaine dependence. J Psychoactive Drugs 2001; 33: 283-287.
146. Rubio G, López-Muñoz F, Alamo C. Effects of lamotrigine in patients with bipolar disorder and alcohol dependence. Bipolar Disord 2006; 8: 289-293.
147. Brown ES, Nejtek VA, Perantie DC, Orsulak PJ, Bobadilla L. Lamotrigine in patients with bipolar disorder and cocaine dependence. J Clin Psychiatry 2003; 64: 197-201.
148. Brown ES, Jeffress J, Liggin JDM, Garza M, Beard L. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry 2005; 66: 756-760.
149. Brown ES, Garza M, Carmody TJ. A randomized, double-blind, placebo-controlled add-on trial of quetiapine in outpatients with bipolar disorder and alcohol use disorders. J Clin Psychiatry 2008; 69: 701-705.
150. Martinotti G, Andreoli S, Di Nicola M, Di Giannantonio M, Sarchiapone M, Janiri L. Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics. Hum Psychopharm Clin 2008; 23: 417-424.
151. Geller B, Cooper TB, Sun K et al. Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolesc Psychiatry 1998; 37: 171-178.
152. Prisciandaro JJ, Brown DG, Brady KT, Tolliver BK. Comorbid anxiety disorders and baseline medication regimens predict clinical outcomes in individuals with co-occurring bipolar disorder and alcohol dependence: Results of a randomized controlled trial. Psychiatry Res 2011; 188: 361-365.
153. Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 2005; 7: 424-430.
154. Goldstein BI, Fagiolini A, Houck P, Kupfer DJ. Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. Bipolar Disord 2009; 11: 657-662.
155. van Winkel R, De Hert M, van Eyck D et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord 2008; 10: 342-348.
156. Chien IC, Chang KC, Lin CH, Chou YJ, Chou PS. Prevalence of diabetes in patients with bipolar disorder in Taiwan: a population-based national health insurance study. Gen Hosp Psychiatry 2010; 32: 577-582.
157. Malhi GS, Bargh DM, McIntyre R et al. Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder. Bipolar Disord 2012; 14 (Suppl. 2): 1-21.
158. Ng F, Mammen OK, Wilting I et al. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord 2009; 11: 559-595.
159. Moreno C, Laje G, Blanco C, Jiang H, Schmidt AB, Olfson M. National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch Gen Psychiatry 2007; 64: 1032-1039.
160. Soutullo CA, Escamilla-Canales I, Wozniak J, Gamazo-Garran P, Figueroa-Quintana A, Biederman J. Pediatric bipolar disorder in a Spanish sample: features before and at the time of diagnosis. J Affect Disord 2009; 118: 39-47.
161. Jolin EM, Weller EB, Weller RA. Prepubertal bipolar disorder: proper diagnosis should lead to better treatment response. Curr Psychiatry Rep 2005; 7: 104-111.
162. McClellan J, Kowatch R, Findling RL, Work Group on Quality I. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2007; 46: 107-125.
163. Thomas T, Stansifer L, Findling RL. Psychopharmacology of pediatric bipolar disorders in children and adolescents. Pediatr Clin North Am 2011; 58: 173-187.
164. McNamara RK, Nandagopal JJ, Strakowski SM, DelBello MP. Preventative strategies for early-onset bipolar disorder: towards a clinical staging model. CNS Drugs 2010; 24: 983-996.
165. Kowatch RA, Suppes T, Carmody TJ et al. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2000; 39: 713-720.
166. Tohen M, Kryzhanovskaya L, Carlson G et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 2007; 164: 1547-1556.
167. DelBello MP, Kowatch RA, Adler CM et al. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry 2006; 45: 305-313.
168. DelBello MP, Findling RL, Wang P et al. Efficacy and safety of ziprasidone in pediatric bipolar disorder. Poster presentation at the 161st Annual Meeting of the American Psychiatric Association, May 3-8, 2008, Washington, DC, USA.
169. Findling R, DelBello M, Wang P, Gundapaneni B, Versavel M, Karayal O. Safety and efficacy of ziprasidone in pediatric bipolar disorder. Eur Neuropsychopharmacol 2009; 19 (Suppl. 3): 682-683.
170. Haas M, DelBello MP, Pandina G et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2009; 11: 687-700.
171. Findling RL, Nyilas M, Forbes RA, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2009; 70: 1441-1451.
172. DelBello MP, Schwiers ML, Rosenberg HL, Strakowski SM. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002; 41: 1216-1223.
173. DelBello MP, Chang K, Welge JA et al. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord 2009; 11: 483-493.
174. Chang K, Saxena K, Howe M. An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry 2006; 45: 298-304.
175. Patel NC, DelBello MP, Bryan HS et al. Open-label lithium for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry 2006; 45: 289-297.
176. Findling RL, McNamara NK, Youngstrom EA et al. Double-blind 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005; 44: 409-417.
177. Findling RL, McNamara NK, Youngstrom EA et al. An Open-Label Study of Aripiprazole in Children with a Bipolar Disorder. J Child Adolesc Psychopharmacol 2011; 21: 345-351.
178. Pavuluri MN, Henry DB, Carbray JA, Sampson GA, Naylor MW, Janicak PG. A one-year open-label trial of risperidone augmentation in lithium nonresponder youth with preschool-onset bipolar disorder. J Child Adolesc Psychopharmacol 2006; 16: 336-350.
179. Sajatovic M, Chen P. Geriatric Bipolar Disorder. Psychiatr Clin N Am 2011; 34: 319-333.
180. Hirschfeld RMA, Calabrese JR, Weissman MM et al. Screening for bipolar disorder in the community. J Clin Psychiatry 2003; 64: 53-59.
181. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593-602.
182. Depp AC, Lindamer LA, Folsom DP et al. Differences in clinical features and mental health service use in bipolar disorder across the lifespan. Am Journal Geriatr Psychiatry 2005; 13: 290-298.
183. Sajatovic M, Blow FC, Ignacio RV. Psychiatric comorbidity in older adults with bipolar disorder. Int J Geriatr Psychiatry 2006; 21: 582-587.
184. Shulman KI. Lithium for older adults with bipolar disorder: should it still be considered a first-line agent? Drugs Aging 2010; 27: 607-615.
185. Gildengers AG, Mulsant BH, Begley AE et al. A pilot study of standardized treatment in geriatric bipolar disorder. Am J Geriatr Psychiatry 2005; 13: 319-323.
186. Hirschfeld RMA, Bowden CL, Gitlin MJ et al. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159: 1-50.
187. Yatham LN, Kennedy SH, O'Donovan C et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005; 7 (Suppl. 3): 5-69.
188. Chen ST, Altshuler LL, Melnyk KA, Erhart SM, Miller E, Mintz J. Efficacy of lithium vs. valproate in the treatment of mania in the elderly: a retrospective study. J Clin Psychiatry 1999; 60: 181-186.
189. Himmelhoch JM, Neil JF, May SJ, Fuchs CZ, Licata SM. Age, dementia, dyskinesias, and lithium response. Am J Psychiatry 1980; 137: 941-945.
190. Kessing LV, Sondergard L, Kvist K, Andersen PK. Suicide risk in patients treated with lithium. Arch Gen Psychiatry 2005; 62: 860-866.
191. Kessing LV, Sondergard L, Forman JL, Andersen PK. Lithium treatment and risk of dementia. Arch Gen Psychiatry 2008; 65: 1331-1335.
192. Nunes PV, Forlenza OV, Gattaz WF. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry 2007; 190: 359-360.
193. Wijeratne C, Draper B. Reformulation of current recommendations for target serum lithium concentration according to clinical indication, age and physical comorbidity. Aust N Z J Psychiatry 2011; 45: 1026-1032.
194. Noaghiul S, Narayan M, Nelson JC. Divalproex treatment of mania in elderly patients. Am J Geriatr Psychiatry 1998; 6: 257-262.
195. Young RC. Evidence-based pharmacological treatment of geriatric bipolar disorder. Psychiatr Clin North Am 2005; 28: 837-869.
196. Sajatovic M, Calabrese JR, Mullen J. Quetiapine for the treatment of bipolar mania in older adults. Bipolar Disord 2008; 10: 662-671.
197. Sajatovic M, Coconcea N, Ignacio RV et al. Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial. J Clin Psychiatry 2008; 69: 41-46.
198. Madhusoodanan S, Suresh P, Brenner R, Pillai R. Experience with the atypical antipsychotics-risperidone and olanzapine in the elderly. Ann Clin Psychiatry 1999; 11: 113-118.
199. Shulman RW, Singh A, Shulman KI. Treatment of elderly institutionalized bipolar patients with clozapine. Psychopharmacol Bull 1997; 33: 113-118.
200. Correll CU, Frederickson AM, Kane JM, Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry 2006; 67: 575-583.
201. Nemeroff CB, Evans DL, Gyulai L et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001; 158: 906-912.
202. Robillard M, Conn DK. Lamotrigine use in geriatric patients with bipolar depression. Can J Psychiatry 2002; 47: 767-770.
203. Canuto A, Meiler-Mititelu C, Herrmann FR, Delaloye C, Giannakopoulos P, Weber K. Longitudinal assessment of psychotherapeutic day hospital treatment for elderly patients with depression. Int J Geriatr Psychiatry 2008; 23: 949-956.
204. Depp CA, Lebowitz BD, Patterson TL, Lacro JP, Jeste DV. Medication adherence skills training for middle-aged and elderly adults with bipolar disorder: development and pilot study. Bipolar Disord 2007; 9: 636-645.
205. Sajatovic M, Gyulai L, Calabrese JR et al. Maintenance treatment outcomes in older patients with bipolar I disorder. Am J Geriatr Psychiatry 2005; 13: 305-311.
206. Yonkers KA, Wisner KL, Stowe Z et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004; 161: 608-620.
207. Grof P, Robbins W, Alda M et al. Protective effect of pregnancy in women with lithium-responsive bipolar disorder. J Affect Disord 2000; 61: 31-39.
208. Freeman MP, Smith KW, Freeman SA et al. The impact of reproductive events on the course of bipolar disorder in women. J Clin Psychiatry 2002; 63: 284-287.
209. Lee H-C, Lin H-C. Maternal bipolar disorder increased low birthweight and preterm births: a nationwide population-based study. J Affect Disord 2010; 121: 100-105.
210. Galbally M, Roberts M, Buist A, Perinatal Psychotropic Review G. Mood stabilizers in pregnancy: a systematic review. Aust N Z J Psychiatry 2010; 44: 967-977.
211. National Collaborating Centre for Mental Health. Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. Leicester: British Psychological Society and and Royal College of Psychiatrists, 2006: 1-592.
212. Vajda FJE, Hitchcock A, Graham J, O'Brien T, Lander C, Eadie M. The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Aust N Z J Obstet Gynaecol 2007; 47: 468-474.
213. Diav-Citrin O, Shechtman S, Bar-Oz B, Cantrell D, Arnon J, Ornoy A. Pregnancy outcome after in utero exposure to valproate: evidence of dose relationship in teratogenic effect. CNS Drugs 2008; 22: 325-334.
214. Wide K, Winbladh B, Tomson T, Kallen B. Body dimensions of infants exposed to antiepileptic drugs in utero: observations spanning 25years. Epilepsia 2000; 41: 854-861.
215. Jacobson SJ, Jones K, Johnson K et al. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet 1992; 339: 530-533.
216. Troyer WA, Pereira GR, Lannon RA, Belik J, Yoder MC. Association of maternal lithium exposure and premature delivery. J Perinatol 1993; 13: 123-127.
217. Cohen LS, Friedman JM, Jefferson JW, Johnson EM, Weiner ML. A reevaluation of risk of in utero exposure to lithium. JAMA 1994; 271: 146-150.
218. Gentile S. Neurodevelopmental effects of prenatal exposure to psychotropic medications. Depress Anxiety 2010; 27: 675-686.
219. Newham JJ, Thomas SH, MacRitchie K, McElhatton PR, McAllister-Williams RH. Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study. Br J Psychiatry 2008; 192: 333-337.
220. Goldstein DJ, Corbin LA, Fung MC. Olanzapine-exposed pregnancies and lactation: early experience. J Clin Psychopharmacol 2000; 20: 399-403.
221. Gentile S. Prophylactic treatment of bipolar disorder in pregnancy and breastfeeding: focus on emerging mood stabilizers. Bipolar Disord 2006; 8: 207-220.
222. Dickson RA, Hogg L. Pregnancy of a patient treated with clozapine. Psychiatr Serv 1998; 49: 1081-1083.
223. Di Michele V, Ramenghi L, Sabatino G. Clozapine and lorazepam administration in pregnancy. Eur Psychiatry 1996; 11: 214.
224. Ernst CL, Goldberg JF. The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatry 2002; 63 (Suppl. 4): 42-55.
225. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. National Birth Defects Prevention Study. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007; 356: 2684-2692.
226. Louik C, Lin A, Werler M, Hernandez-Diaz S, Mitchell A. First-Trimester Use of Selective Serotonin-Reuptake Inhibitors and the Risk of Birth Defects. N Engl J Med 2007; 365: 2675-2683.
227. Cunnington MC. The International Lamotrigine pregnancy registry update for the epilepsy foundation. Epilepsia 2004; 45: 1468.
228. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009; 11: 225-255.
229. Anderson EL, Reti IM. ECT in pregnancy: a review of the literature from 1941 to 2007. Psychosom Med 2009; 71: 235-242.
230. Viguera AC, Tondo L, Koukopoulos AE, Reginaldi D, Lepri B, Baldessarini RJ. Episodes of mood disorders in 2, 252 pregnancies and postpartum periods. Am J Psychiatry 2011; 168: 1179-1185.
231. Sharma V, Burt VK, Ritchie HL. Assessment and treatment of bipolar II postpartum depression: A review. J Affect Disord 2010; 125: 18-26.
232. Gitlin M. Treatment-resistant bipolar disorder. Mol Psychiatry 2006; 11: 227-240.
233. Pacchiarotti I, Mazzarini L, Colom F et al. Treatment-resistant bipolar depression: towards a new definition. Acta Psychiatr Scand 2009; 120: 429-440.
234. Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry 2008; 69 (Suppl. 1): 4-17.
235. Ketter TA. Monotherapy versus combined treatment with second-generation antipsychotics in bipolar disorder. J Clin Psychiatry 2008; 69 (Suppl. 5): 9-15.
236. Sachs GS. Treatment-resistant bipolar depression. Psychiatr Clin North Am 1996; 19: 215-236.
237. Van Riel WG, Vieta E, Martinez-Aran A et al. Chronic mania revisited: factors associated with treatment non-response during prospective follow-up of a large European cohort (EMBLEM). World J Biol Psychiatry 2008; 9: 313-320.
238. Mohan TSP, Tharyan P, Alexander J, Raveendran NS. Effects of stimulus intensity on the efficacy and safety of twice-weekly, bilateral electroconvulsive therapy (ECT) combined with antipsychotics in acute mania: a randomised controlled trial. Bipolar Disord 2009; 11: 126-134.
239. Benedetti F, Barbini B, Fulgosi MC et al. Combined total sleep deprivation and light therapy in the treatment of drug-resistant bipolar depression: acute response and long-term remission rates. J Clin Psychiatry 2005; 66: 1535-1540.
240. Malhi GS, Adams D. Are guidelines in need of CPR? The development of clinical practice recommendations (CPR). Acta Psychiatri Scand Supplementum 2009; 119 (Suppl. 439): 5-7.
241. Tohen M, Vieta E, Calabrese J et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60: 1079-1088.
242. van der Loos MLM, Mulder PG, Hartong EGTM et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2009; 70: 223-231.
243. Lauder SD, Berk M, Castle DJ, Dodd S, Berk L. The role of psychotherapy in bipolar disorder. Med J Aust 2010; 193 (Suppl. 4): 31-35.
244. Thase ME, Sachs GS. Bipolar depression: pharmacotherapy and related therapeutic strategies. Biol Psychiatry 2000; 48: 558-572.
245. Medda P, Perugi G, Zanello S, Ciuffa M, Rizzato S, Cassano GB. Comparative response to electroconvulsive therapy in medication-resistant bipolar I patients with depression and mixed state. J ECT 2010; 26: 82-86.
246. Hadley D, Anderson BS, Borckardt JJ et al. Safety, tolerability, and effectiveness of high doses of adjunctive daily left prefrontal repetitive transcranial magnetic stimulation for treatment-resistant depression in a clinical setting. J ECT 2011; 27: 18-25.
247. Nierenberg AA, Alpert JE, Gardner-Schuster EE, Seay S, Mischoulon D. Vagus nerve stimulation: 2-year outcomes for bipolar versus unipolar treatment-resistant depression. Biol Psychiatry 2008; 64: 455-460.
248. Papatheodorou G, Kutcher S. The effect of adjunctive light therapy on ameliorating breakthrough depressive symptoms in adolescent-onset bipolar disorder. J Psychiatry Neurosci 1995; 20: 226-232.
249. Wu JC, Kelsoe JR, Schachat C et al. Rapid and sustained antidepressant response with sleep deprivation and chronotherapy in bipolar disorder. Biol Psychiatry 2009; 66: 298-301.
250. Papadimitriou GN, Dikeos DG, Soldatos CR, Calabrese JR. Non-pharmacological treatments in the management of rapid cycling bipolar disorder. J Affect Disord 2007; 98: 1-10.
251. Denicoff KD, Smith-Jackson EE, Bryan AL, Ali SO, Post RM. Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder. Am J Psychiatry 1997; 154: 1456-1458.
252. Solomon DA, Ryan CE, Keitner GI et al. A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder. J Clin Psychiatry 1997; 58: 95-99.
253. Baethge C, Baldessarini RJ, Mathiske-Schmidt K et al. Long-term combination therapy versus monotherapy with lithium and carbamazepine in 46 bipolar I patients. J Clin Psychiatry 2005; 66: 174-182.
254. Tohen M, Chengappa KNR, Suppes T et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004; 184: 337-345.
255. Nierenberg AA, Ostacher MJ, Calabrese JR et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 2006; 163: 210-216.
256. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004; 161: 564-566.
257. Malempati RN, Bond DJ, Yatham LN. Depot risperidone in the outpatient management of bipolar disorder: a 2-year study of 10 patients. Int Clin Psychopharmacol 2008; 23: 88-94.
258. Chang JS, Ha K-S, Young Lee K, Sik Kim Y, Min Ahn Y. The effects of long-term clozapine add-on therapy on the rehospitalization rate and the mood polarity patterns in bipolar disorders. J Clin Psychiatry 2006; 67: 461-467.
259. Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999; 156: 1164-1169.
260. Vieta E, Torrent C, Garcia-Ribas G et al. Use of topiramate in treatment-resistant bipolar spectrum disorders. J Clin Psychopharmacol 2002; 22: 431-435.
261. Calabrese JR, Keck PE Jr, McElroy SL, Shelton MD. A pilot study of topiramate as monotherapy in the treatment of acute mania. J Clin Psychopharmacol 2001; 21: 340-342.